Clinical trial CRP apheresis after myocardial infarction published
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).